Get started
Author

Stephanie B. Greene

Observed names: Greene, Stephanie B., S. Greene, Stephanie Greene
ORCID: 0000-0002-7432-5639
Observed ORCID: 0000-0002-7432-5639
OpenAlex ID: A5103097904
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
2016 · Howard I. Scher, David Lu, et al. · JAMA Oncology · 658
PDF
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2017 · Howard I. Scher, Ryon P. Graf, et al. · Cancer Research · 136
Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization
2015 · Shannon L. Werner, Ryon P. Graf, et al. · Journal of Circulating Biomarkers · 132
PDF
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2017 · Daniel J. Boffa, Ryon P. Graf, et al. · Cancer Epidemiology Biomarkers & Prevention · 71
BMP signaling in congenital heart disease: New developments and future directions
2011 · Jun Wang, Stephanie B. Greene, et al. · Birth Defects Research Part A Clinical and Molecular Teratology · 70
Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis
2016 · Stephanie B. Greene, Angel E. Dago, et al. · PLoS ONE · 56
PDF
Androgen receptor expression on circulating tumor cells in metastatic breast cancer
2017 · Takeo Fujii, James M. Reuben, et al. · PLoS ONE · 22
PDF
Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization
2015 · Shannon L. Werner, Ryon P. Graf, et al. · Journal of Circulating Biomarkers · 14
PDF
Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer
2019 · Terence W. Friedlander, Christopher Welty, et al. · The Journal of Urology · 10
AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy.
2016 · Howard I. Scher, Ryon Graf, et al. · Journal of Clinical Oncology · 5
CTC phenotype classifier to identify mCRPC patients (pts) with high genomic instability CTCs and to predict failure of androgen ecreptor signaling (AR Tx) and taxane (T) systemic therapies.
2016 · Howard I. Scher, Adam Jendrisak, et al. · Journal of Clinical Oncology · 4
Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients.
2016 · Howard I. Scher, Ryon Graf, et al. · Journal of Clinical Oncology · 4
A single cell genomic signature to detect homologous recombination deficiency (HRD) and PARP inhibitors sensitivity using patient's circulating tumor cells (CTCs).
2016 · Gordon Vansant, Angel E Dago, et al. · Journal of Clinical Oncology · 3
Single cell phenogenomic subtyping of circulating tumor cells (CTCs) identify intercellular tumor heterogeneity (het) and multiple resistance mechansisms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2017 · Howard I. Scher, Ryon Graf, et al. · Journal of Clinical Oncology · 2
The use of whole genome copy number variation (CNV) to measure genomic instability in mCRPC CTCs.
2016 · Yipeng Wang, Stephanie Greene, et al. · Journal of Clinical Oncology · 2
Abstract 1584: Analytical and clinical validation of the Epic Circulating Tumor Cell (CTC) Platform: enrichment-free CTC detection and biomarker characterization
2015 · Ryon P. Graf, David T. Valenta, et al. · Cancer Research · 2
Data from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Supplementary Methods & Figures S1-S5 from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023 · Howard I. Scher, Ryon P. Graf, et al.
Figure S1 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Figure S2 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Table S1 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Figure S3 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
Figure S1 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
PDF
Table S1 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
PDF
Figure S3 from Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2023 · Daniel J. Boffa, Ryon P. Graf, et al.
PDF
Works count: 36
Citation count: 1,191
H-index: 9
I10-index: 9
Year
Topic
Type